Dr. Reisfeld’s research interests lie in areas of biological, biomedical, and environmental science that are relevant to human health. His focus, at present, is in examining the fate and effects of xenobiotics (foreign compounds, such as drugs and toxicants) in the body, including issues such as biodistribution, clearance, metabolism, pharmacological effect, and toxicity. As a OneHealth Institute Fellow, he is involved in projects that are highly interdisciplinary in nature and cross traditional boundaries between human, animal, and environmental health.
His current projects include (i) developing a computational framework to help the US FDA assess the bioequivalence of generic drugs, (ii) creating a new method to establish public health indicators and allowable exposures relevant to organophosphorus insecticides, (iii) employing computational methods coupled with targeted experimentation for the analysis and prediction of xenobiotic metabolism, (iv) using physiologically-based pharmacokinetic and pharmacodynamic modeling, and Bayesian and Monte Carlo analyses to aid in the assessment of risk associated with environmental pollutant exposure and in the optimization of drug regimens for infectious disease treatment, (v) exploring the impact of toxicant exposure on epigenetic changes using multiscale ‘systems biology’ approaches, and (vi) utilizing mobile health technologies to promote ‘popular epidemiology’ and community engagement in wellness.
Prior to coming to Colorado State University, Dr. Reisfeld was a postdoctoral fellow in the Department of Biomedical Engineering at The Johns Hopkins School of Medicine. He then took a position as Senior Staff Engineer at United Technologies Corporation where he conducted applied research and co-lead the develop of a number of new products.